PDCD1 and neoplasm: Our data, based on transcriptome analysis and immunohistochemistry (IHC) of B cells in ESCC tumor tissues, suggest an association of B cells in the tumor microenvironment (TME) with improved efficacy of anti-PD-1 therapy in patients with ESCC.